Jephte Rodriguez Martinez, MD
General Practice · Mayaguez, PRNPI 1023190071
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $438 and has fallen 76.1% since, to $105 in 2025. Among general practice clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 69 payments — averaging $22.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- PBG Puerto Rico LLC$344
- AstraZeneca$337
- Sanofi-aventis U.S. LLC$266
- Hikma Pharmaceuticals USA$145
- Merck$126
- Exact Sciences$116
- plus $231 from 5 others
What the payments were for
- Food & beverage$1,565100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| PBG Puerto Rico LLC | 18 | $344 |
| AstraZeneca | 18 | $337 |
| Sanofi-aventis U.S. LLC | 11 | $266 |
| Hikma Pharmaceuticals USA | 6 | $145 |
| Merck | 3 | $126 |
| Exact Sciences | 4 | $116 |
| Boston Scientific | 1 | $71 |
| Johnson & Johnson | 3 | $70 |
| Boehringer Ingelheim | 3 | $56 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Pfizer Pharmaceuticals LLC | 1 | $12 |
How this compares
$1,565 in reported general payments places this provider in the 90th percentile of 3,586 general practice providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 108 | $107,470 |
| XareltoRivaroxaban | 67 | $75,552 |
| EliquisApixaban | 56 | $62,067 |
| TrulicityDulaglutide | 40 | $54,979 |
| JanuviaSitagliptin Phosphate | 56 | $46,656 |
| EntrestoSacubitril/Valsartan | 32 | $31,258 |
| SynthroidLevothyroxine Sodium | 219 | $26,363 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 86 | $25,150 |
| JardianceEmpagliflozin | 12 | $17,284 |
| Candesartan Cilexetil | 110 | $15,035 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $13,489 |
| LantusInsulin Glargine,hum.Rec.Anlog | 71 | $13,032 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $11,788 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $11,637 |
| JanumetSitagliptin Phos/Metformin Hcl | 18 | $11,577 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $337 | $114,388130 claims |
| Johnson & JohnsonXarelto | $70 | $75,55267 claims |
| MerckJanuvia, Janumet Xr, Janumet | $126 | $70,02187 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Stiolto Respimat | $56 | $41,58455 claims |
| Sanofi-aventis U.S. LLCLantus, Soliqua 100-33 | $266 | $24,66982 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,586 general practice providers in Puerto Rico.
Other general practice in Mayaguez
- Julio BacoMayaguez$268K
- Luis CamachoMayaguez$19K
- Efrain Arroyo PenaMayaguez$4K
- Wilfredo CuevasSan Lorenzo$530K
- Soria Diaz BaezPonce$192K
- Carlos RomanCanovanas$140K
- William E TorresSan Juan$86K
- Rafael Mendoza RodriguezPonce$77K
- Frank Perez NogueiraSan German$70K
- Vivian Tamayo AgraitSan Juan$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.